10 Fleet Place
142 articles about BTG plc
Boston Scientific Corporation announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement.
BTG plc, the global healthcare company, highlighted the first publication of National Comprehensive Cancer Network pediatric acute lymphoblastic leukemia guidelines including consideration of Voraxaze®.
BTG plc announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine.
Arizona Patients Successfully Receive the World’s First Bioconvertible IVC Filter Commercially Offered In US
BTG plc today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter.
Transaction would expand peripheral interventions portfolio with minimally-invasive treatments for cancers and vascular conditions
Less than a week after Boston Scientific announced that it was undergoing a restructuring that could result in some job losses, the company announced that it will acquire U.K.-based BTG plc., a surgical device manufacturer for about $4.2 billion.
BTG Sentry Bioconvertible IVC Filter 2-year Study Results Show Zero Tilt, Migration, Perforation, Fracture, or Embolization
BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances (VIVA) conference in Las Vegas.
Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman
Exclusive worldwide licence deal adding to Carrick's rapid pipeline expansion
Updated label describes extended shelf life and removal of mercury
Strategic partnership with the PERT ConsortiumTM to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERTTM programs across the U.S.
BTG plc highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California.
BTG Release: Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS Therapy Protocols for Pulmonary Embolism
At full enrollment, KNOCOUT PE is expected to include up to 100 centers internationally.
BTG today announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere, Northwestern University, Illinois has adopted Y90 TARE with TheraSphere as the primary trans-arterial LRT for patients with hepatocellular carcinomalimited to the liver.
BTG plc Release: Vistogard And Voraxaze Added To Revised Guidelines For Stocking Of Antidotes In U.S. Hospitals
BTG plc Release: ACCESS PTS Study Demonstrates Efficacy Of EKOS Therapy For Post-Thrombotic Syndrome
BTG plc Release: New Study Shows Patients Treated With CroFab Have Improved Recovery From Copperhead Envenomation
BTG plc Release: New Study Shows IO Loop Improves Patient Follow-Up, Engagement And Satisfaction Following Treatment With TheraSphere
BTG plc Release: OPTALYSE PE Study Demonstrates Safety And Efficacy Of Shorter, Lower Dose EKOS Therapy For Pulmonary Embolism